Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Long-Term Deferred Tax (2020 - 2025)

Vycor Medical has reported Long-Term Deferred Tax over the past 6 years, most recently at $469000.0 for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 13.29% to $469000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $469000.0 through Dec 2025, up 13.29% year-over-year, with the annual reading at $469000.0 for FY2025, 13.29% up from the prior year.
  • Long-Term Deferred Tax was $469000.0 for Q4 2025 at Vycor Medical, up from $414000.0 in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $4.2 million in Q4 2023 and troughed at $414000.0 in Q4 2024.
  • The 5-year median for Long-Term Deferred Tax is $509000.0 (2021), against an average of $1.9 million.
  • Year-over-year, Long-Term Deferred Tax soared 720.24% in 2022 and then crashed 90.09% in 2024.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $509000.0 in 2021, then soared by 720.24% to $4.2 million in 2022, then grew by 0.02% to $4.2 million in 2023, then crashed by 90.09% to $414000.0 in 2024, then increased by 13.29% to $469000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Long-Term Deferred Tax are $469000.0 (Q4 2025), $414000.0 (Q4 2024), and $4.2 million (Q4 2023).